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Abstract
There is in vivo evidence that suggests the genetic diversity of HIV-1 subtypes influence
heterosexual transmission efficiency. To recapitulate sexual transmission in vitro, blocks
of genital tissue were exposed to mixtures of genetically different subtype viruses.
Migrating immune cells were collected and co-cultured with a CD4+ T-cell line permissive
to HIV infection (PM1) to measure dendritic cell virus transfer; HIV-exposed tissues were
cultured separately. Next generation sequencing (NGS) of HIV-1 DNA was used to
quantify relative infection rates of the various challenge viruses, and to assess fitness
differences in infection of the tissue vs. migratory/T cell co-cultures. Our results suggest a
HIV-1 subtype’s ability to replicate in susceptible T cells may be predictive of its ability
to replicate in susceptible tissue-resident cell populations. However, this may not reflect
the ability of a subtype to be transported out of the tissue for infection elsewhere in the
body.
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Summary for Lay Audience
Human Immunodeficiency Virus Type 1 (HIV-1) is the causative agent for AIDS. Since
the start of the epidemic, HIV-1 has evolved rapidly and resulted in different subtypes that
are genetically diverse from one another. These subtypes are what’s driving the number of
new infections worldwide. Studies have shown that the genetic diversity of the different
subtypes contribute to how fast someone will start to experience AIDS. In particular, HIV1 subtype C results in individuals progressing to AIDS at a much slower rate compared to
HIV-1 subtypes A, B, and D. Researchers have speculated that this slower disease
progression may result in more opportunity for new infections due to the fact that these
individuals will likely only seek treatment when they experience AIDS-like symptoms.
This makes sense, as HIV-1 subtype C accounts for greater than 50% of infections
worldwide when compared to the other subtypes. Although increased opportunity for
infection would account for this larger prevalence, the transmission efficiency of the
different subtypes may also play a role. To investigate the transmission efficiencies of the
different subtypes, I infected explants of genital tissue with these different subtypes and
measured their abilities to infect tissue and transmit to susceptible cells. In this study, I
found that the ability of a virus to cause disease progression may be able to predict its
ability to replicate in the tissue itself. However, this may not relate to the ability of a virus
to transmit and infect other parts of the body. Future studies will need to include more
viruses to help further discern the differences in transmission efficiencies between the HIV1 subtypes.
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Chapter 1: Introduction
1.1 HIV-1 Epidemic
Human Immunodeficiency Virus type 1 (HIV-1), the causative agent for Acquired
Immunodeficiency Syndrome (AIDS), was first isolated from a patient in 19831,2. As time
has passed, HIV-1 has become a significant challenge to public and global health and
continues to challenge populations due to the high frequency of undiagnosed infections, a
disproportionate effect on marginalized populations, and the absence of compliance-free
preventative measures and a cure. In 2018, there were 37.9 million people living with
HIV/AIDS worldwide which is irrespective of the fact that 74.9 million people have been
infected with HIV-1 since its discovery3. The effect on the human species is staggering,
with over 35 million losing their life to the battle against HIV/AIDS4. Despite a vast
number of ongoing efforts, 1.7 million people worldwide were newly infected with HIV-1
in 20183 which translates to 3 new infections per minute.
In 2018, 770,000 people died as a result of HIV/AIDS3. This can be seen as an
improvement when compared to an astounding 2 million people dying due to AIDS-related
deaths in 20083. A large part in this reduction of mortality can be attributed to the United
Nations AIDS Program (UNAIDS) 90-90-90 initiative3. This initiative put forth 3 goals:
90% of individuals living with HIV know their status, of those individuals 90% of them
are on antiretroviral (ART) therapy, and 90% of those individuals receiving ART therapy
achieve viral suppression. As of 2018, UNAIDS estimated that 79% of people living with
HIV know their status, of those 78% were receiving ART, and 86% of those achieved viral
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suppression3. The trends are in the right direction, but there is still a lot of work to be done
to achieve the 90-90-90 goals.

Different areas of the world are affected by the HIV-1 epidemic in different ways. SubSaharan Africa accounts for approximately 70% of individuals living with HIV-1 which
translates to an adult prevalence of approximately 4.1%4. As a comparison, every other
WHO region has a prevalence of less than 1%. For example, the Americas are the next
highest, with an adult prevalence of 0.5%. Even within Africa, there are differences in
burden of disease. South Africa has an estimated prevalence of 19.2% and is the country
with the largest population of individuals living with HIV-1. In contrast, the prevalence of
HIV-1 in Senegal is around 0.5%4. For new infections globally, heterosexual transmission
has been reported to account for 70% of newly acquired infections5. The remainder of
newly acquired infections can be attributed to other major routes of transmission. These
include men who have sex with men (MSM), maternal-infant infection, and injection drug
use3. Although heterosexual transmission accounts for the majority of newly acquired
infections, the transmission probability per exposure event for men and women are low,
ranging from 1 in 700 to 1 in 3000 and 1 in 200 to 1 in 2000, respectively5. With
heterosexual intercourse being the major route of transmission in Sub-Saharan Africa,
women account for approximately 58% of individuals living with HIV-1 in Sub-Saharan
Africa6. Consequently, decreasing heterosexual transmission of HIV-1 will be an important
step towards remedying the number of new infections and mitigating the HIV-1 disease
burden across the world.
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1.2. HIV-1 Life Cycle
To understand how HIV-1 has impacted so many lives, it is important to understand its life
cycle in the human host. The intricacies of HIV-1 replication in human cells provide the
basis for vaccine designs and cure strategies; the details of HIV-1 replication in susceptible
human cells are well established7 and will be detailed here. A direct interaction of HIV-1’s
envelope protein, gp120 (Figure 1), and the CD4 receptor on human immune cells is one
requirement for infection. However, this interaction is not sufficient to begin entry into
cells and one of two chemokine receptors, CCR5 and CXCR4, are also required for this
process. In general, certain HIV-1 viruses preferentially bind to CCR5 or CXCR4. Once
binding of CD4 and one of CCR5 or CXCR4 occurs, fusion of the HIV-1 envelope and the
host cell membrane begins, culminating in the release of the viral capsid (Figure 1) into
the cytoplasm. Reverse transcription inside the capsid initiates, with HIV-1’s native reverse
transcriptase introducing a plethora of DNA replication errors in the process of creating
double stranded DNA (dsDNA) from its own RNA genome. This high error rate in reverse
transcription is the main reason cure and vaccine strategies have been so difficult – HIV-1
evolves very rapidly. Shortly, the dsDNA is transported into the nucleus for integration
into the host genome via HIV-1’s integrase protein. After this point the integrated DNA,
or proviral DNA, utilizes host cell transcription machinery and mRNA transcripts are
generated. These RNA molecules are then translated to produce all the necessary structural
and enzymatic proteins of HIV-1 leading to budding and release of new HIV-1 particles.
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Figure 1. HIV-1 Structure
Different components of HIV-1 involved in HIV-1 infection, transmission, and replication.
Gp120, the only surface exposed protein on HIV-1, is an important component of the HIV1 envelope involved in infection and transmission. It is involved in the first interaction
between HIV-1 and CD4+ T cells. The capsid houses the viral RNA genome.
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1.3 HIV-1 Genetic Diversity
Since its discovery, the evolutionary history of HIV-1 and its relation to the epidemic has
been of particular interest in the field. HIV-1 accounts for over 98% of infections and is
the main driver of new infections and AIDS-related disease worldwide8. It has established
itself as the primary HIV type for research and treatment efforts. Within HIV-1 there are
three lineages: the main (M) group, the new (N) group, and the outlier (O) group9,10. Group
M dominates the other groups in its prevalence11, and researchers speculate that a single
transmission of HIV-1 from group M coincided with the expansion of the epidemic10. Over
time, divergent evolution of HIV-1 group M has resulted in distinct and diverse subtypes;
these subtypes are: A, B, C, D, F, G, H, J, and K and they are also not distributed evenly
worldwide7. HIV-1 subtypes A, B, and D account for 12%, 10%, and 3% of infections
worldwide12, respectively, while ‘pure’ subtype C or HIV-1 recombinant forms with the
envelope gene of subtype C are responsible for greater than 50% of the HIV-1 infections
worldwide12. Recombination can occur when an infected cell has two different proviruses13.
Thus if both transcripts are encapsulated into a virion, the reverse transcriptase can jump
between the two templates creating a newly synthesized DNA sequence that is recombinant.
Currently, there are 98 known circulating recombinant forms of HIV14. Taken together, the
investigation of HIV-1 group M and the different dominant subtypes is important to attempt
to decrease the number of new infections. Transmission of HIV-1 is multi-faceted and
involves multiple considerations.

1.4. HIV-1 Infection in Genital Tissue
HIV-1 preferentially replicates and propagates in CD4+ T cells in the mucosa, submucosa,
draining lymphatics, and systemic lymphatic tissues15. One of the most important, if not
5

the most important factor for predicting HIV-1 infection after exposure is plasma viral load
(vL) of the infecting partner16–18. For HIV-1 discordant monogamous couples, individuals
with plasma levels <400 HIV RNA copies/mL did not transmit to their partners19,20.
Additional studies investigated the effect of viral load on transmission risk and it was
determined that for every log increase in viral load the risk of transmission increased by a
factor of 2.4518.

Using virions labelled with a photoactivatable GFP-Vpr (PA-GFP), Ann M. Carias and her
colleagues proposed a model of how HIV-1 interacts with the female reproductive tract
(FRT)21. When the epithelia of the FRT is intact, HIV-1 virions rarely penetrate and even
more rarely into areas with potential target cells. When cellular junctions are absent or
degraded, or when the epithelium loses its integrity, virions can readily penetrate the FRT
(Figure 2A). As a result, virions have a greater chance of interacting with resident
intraepithelial Langerhans Cells (LCs) and other susceptible cells. Inflammation of the
FRT has also been shown to increase the odds of HIV-1 interacting with target cells in the
mucosa22–26. The recruitment of susceptible cells to the FRT alongside mechanisms such
as cell junction degradation can all increase the likelihood of HIV-1 transmitting. Carias
and colleagues were also able to extrapolate and estimate the number of virions that
penetrate the lower FRT per coital act. They estimated that when the acutely-infected donor
deposits their viral population into the recipient, potentially 1.49 x 104 virions penetrate the
squamous epithelium of the ectocervix per coital act. For the endocervix, they estimate a
potential 3.40 x 103 penetrates the simple columnar epithelium.
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The specific cell types that HIV-1 infect after exposure in the mucosa are CD4+ T cells,
dendritic cells (DCs), or macrophages27,28. As briefly mentioned before, in foreskin29 and
cervix30 activated CD4+ T cells and immature Langerhans cells27 are distributed
throughout the tissue and susceptible to infection. It is heavily debated whether cell-free
virus or cell-associated virus is responsible for sexual transmission and systemic
infection31–33. However, in vitro studies have shown that cell-associated HIV-1
transmission is much more efficient, likely because of concentrated production at
intercellular contact points, directional secretion through specialized intercellular synapses,
and possibly decreased vulnerability of the virus to host restriction factors and antiviral
factors in the environment during transmission34–40. In general, dendritic cells are involved
in the uptake and processing of antigens. Trans-infection has been described as a process
where dendritic cells will transport the transmitted virus into areas such as the lymphoid
tissue and present the virus, resulting in infection of susceptible T cells41. To demonstrate
this, a study used vaginal explant tissue infected with HIV-1 and showed that transmitted
viruses bound to DCs, DCs transported them through the mucosa, and subsequently
presented HIV-1 to T cells42 (Figure 2B). Other studies have also shown the ability of
epidermal Langerhans cells and dermal DC-SIGN+ dendritic cells to bind infectious viral
particles and present them to T cells43–45. Furthermore, when cervical explant tissue was
inoculated with HIV-1, significant trans infectivity was detected with budding of virions
in DCs harvested from supernatant19,20. Overall, cell-to-cell HIV-1 transmission is an
important process and dendritic cells seem to play a critical role in the presentation of HIV1 viruses to T cells, either in the mucosa or in lymphoid tissue.
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The investigation of cell-free HIV-1 transmission is also important, as CD4+ T cells are
present in the lamina propria of the vagina, ectocervix, and endocervix and CD4 plays an
important role in the infection of T cells. Studies have shown HIV-1 poorly infects cells
expressing CCR5 with low levels of CD446–48. Moreover, models of SIV transmission have
shown that the number of mucosal CD4+/CCR5+ T cells is a key determinant of HIV-1
acquisition risk48. Overall, HIV-1 is very effective at targeting and infecting CD4+ T cells
in the mucosa28,49,50 (Figure 2C).

1.4.1 HIV-1 Infection in Male Genital Tract
Most of our knowledge about heterosexual transmission of HIV-1 comes from studies done
in women. However, studies in men have supported the well-documented findings in
women that have already been discussed here. In circumcision studies, it was determined
that male circumcision reduces HIV-1 infection in heterosexual men by 60%51. This
suggests that foreskin is the major site of HIV-1 infection in men. In the foreskin, there are
many susceptible cells, such as Th17 cells, present for HIV-1 infection52. These CD4+ cells
express high levels of CCR5 and have enhanced in vitro HIV-1 susceptibility53,54.
Moreover, trans-infection by dendritic cells have been observed through in vitro infections
of the inner foreskin55. In short, many of the mechanisms described in women are most
likely to occur in the male genital tract as well, with foreskin being the primary anatomical
site for infection56–58.

8

Figure 2. Schematic of HIV-1 transmission in the cervix
A diverse population of HIV-1 is deposited into the uninfected individual. (A) When the
epithelium loses its integrity, HIV-1 virions can penetrate the epithelium and interact
with susceptible cells. (B) Trans-infection can occur, where tissue resident Langerhans
cells can bind to HIV-1 and transport them to areas with susceptible CD4+CCR5+ T
cells. (C) Even still, HIV-1 is efficient at targeting and infecting CD4+CCR5+ T cells in
the tissue.
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1.5 HIV-1 Transmission Fitness may be different than HIV-1 Pathogenic
Fitness
1.5.1. HIV-1 Transmission Bottleneck
Although the HIV-1 infected donor deposits a diverse viral population into the recipient
during sexual intercourse, the majority of the time only 1 single viral variant penetrates the
mucosal barrier and establishes systemic infection. In fact, this phenomenon occurs in
approximately 80% of heterosexual transmission cases59,60. Termed the “transmission
bottleneck”, it is still not very well understood. It should be noted that the narrowing of the
viral population can occur in both the donor and the recipient as well as in different
anatomical compartments. For example, there is evidence to suggest that the viral
population present in the infected donor’s blood is different than the viral population in the
same individual’s genital tract61–64. More specifically, it is argued that the viruses in the
genital tract are under different selective pressures than those in the blood. However, the
focus here will be on the bottleneck that occurs in the recipient mucosa, which is where the
most severe bottleneck occurs during transmission65.

Shortly after infection, the newly infected host will have a mostly homogenous viral variant
population present in their blood66. This viral variant is termed the transmitted/founder (T/F)
virus and will start to evolve as viral replication occurs. Consistent with this, a more diverse
viral population is observed in the blood of a host that has reached chronic infection. The
cycle continues if the host remains untreated, where a single viral variant is transmitted
from a diverse viral population to an uninfected individual. Building upon this idea, Dr.
Katja Klein and her colleagues sought to characterize the sequence diversity of HIV-1
10

during early infection between two compartments: the female reproductive tract (FRT) and
the blood67. They compared the intra-patient diversity of the C2-V3 env region (gp120)
between matched cervical and blood samples from 72 women recruited from Uganda and
Zimbabwe. Their findings showed that within seven months of being diagnosed of HIV-1
infection, there was higher HIV-1 env diversity in the genital tract compared to the plasma
of these patients. This study further showcases that in spite of a diverse viral population
being deposited during sexual transmission, when systemic infection is first established it
is characterized by a more homogenous viral population.

It is heavily debated whether the HIV-1 bottleneck is due to stochastic events or whether
there are actually selective pressures present that dictate the phenotype of the virus that is
transmitted. It was first discovered that HIV-1 targeted CD4+ T cells that expressed CCR5
or CXCR4 co-receptors for use of entry into the cell68. However, in the majority of cases
the virus that is sexually transmitted is homogenous66,69 and preferentially uses CCR5 as a
co-receptor70. Through observations of individuals who lack a functional gene for the
CCR5 receptor, these specific individuals were completely resistant to acquiring HIV-1
through sexual transmission71. This suggests that all of sexual transmission occurs through
viruses using CCR5 as a co-receptor. This is contrasted with transmission of HIV-1 through
blood, where viruses that preferentially use CXCR4 can also be transmitted65. This may
mean there are different and unique viral characteristics that are needed for fitness in the
tissue vs. the blood.

In addition to the exclusive use of CCR5, T/F envelopes have been shown to have shorter
surface-exposed variable loops (gp120), fewer N-linked glycosylation sites, and more
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sialyation in comparison to chronic viruses72–74. This is in contrast to characteristics of
viruses that allow it to evade broadly neutralizing antibodies (bNAbs). It seems that only
once infection occurs, the virus mutates and gains the ability to evade bNAbs by increasing
the length of variable loops, adding N-linked glycosylation sites, and altering the
composition of the persistent high mannose patch of gp120 subunits75–77. These changes
help evade immune pressure, allowing for the repeated infection and killing of CD4+ T
cells. Altogether, this suggests that genetic differences between HIV-1 variants can confer
differences in transmission fitness. But more importantly, the phenotype of the T/F virus
that offers a greater fitness advantage in transmission may or may not offer the same fitness
advantage for pathogenicity.

1.5.3 Differences in defining HIV-1 Pathogenic and Transmission fitness
Individuals infected with replication-defective, nef-mutated virus demonstrate that
individuals infected with a virus that has poor replicative fitness progresses to AIDSrelated disease at a slower rate78–80. Moreover, the ability of a virus to replicate in peripheral
blood mononuclear cells (PBMCs) has been shown to correlate with decreasing CD4+ cell
counts and increasing viral load during disease81. Thus, the replicative or pathogenic fitness
of a virus strain can be defined as the relative ex vivo replication capacity of HIV-1 in
CD4+ T cells and PBMCs82–84. In contrast, the ex vivo transmission fitness of a virus used
to be measured by competing HIV-1 isolates in cells of the dendritic lineage, which are
derived from blood monocytes or human skin27,85. However more recently, studies have
begun to employ genital explant tissue to define transmission fitness55,86. Thus, the ex vivo
transmission fitness of a virus can be defined by its ability to penetrate genital explant
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tissue, infect tissue-resident susceptible cell populations, and bind to resident cells that
migrate out of the mucosal layer for trans-infection in susceptible T cells.

1.5.2 Rationale for Possible Attenuation of HIV-1 group M viruses
Both opportunity for infection and transmission efficiency are key factors of pathogen
survival87. As mentioned above, env characteristics of the T/F virus may not confer a fitness
advantage in evading the immune system. One factor that’s important in considering a
pathogen’s ability to cause disease is its ability to evade the immune system. Thus the T/F
virus, the most efficiently transmitted virus, would be anticipated to be less virulent.
However, this decreased virulence would theoretically allow more opportunities to
transmit to uninfected individuals. At the population-level, a virus’ ability to transmit
efficiently and have a greater number of opportunities to infect new hosts would allow it
to survive in the epidemic at a greater capacity.

For an individual who does not have knowledge of their infection, especially during the
acute/early phase of their infection where viral load is the highest, the number of sexual
contacts/encounters directly relates to opportunities for HIV-1 infection in uninfected
individuals88. However, in a population where the number of sexual contacts are decreased,
the period of infection with the highest viral load may be recovered by periods of longer
asymptomatic infection with a more moderate viral load. In other words, individuals with
a more moderate viral load may have more sexual contacts with uninfected individuals
over a longer period of time. While high viral load relates to increased opportunity for new
infections, a lower HIV-1 virulence could lead to longer periods of asymptomatic disease
which could also relate to increased opportunities for new HIV-1 infections. There has
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been a disproportionate expansion of HIV-1 subtype C compared to the other dominant
group M subtypes. Attempts to define the relative pathogenic and transmission fitness’
between the different group M subtypes have been undertaken in hopes of understanding
the differential prevalence around the world. The exceptional genetic diversity between the
group M subtypes could potentially translate to fitness differences.

1.6 Subtypes and Pathogenic Fitness Differences
To determine the relative pathogenic fitness’ of the different HIV-1 group M subtypes,
competition experiments involving the different group M subtypes have been widely
performed. Employing eight HIV-2, six HIV-1 group O, and 15 group M isolates, pairwise competitions in PBMCs were performed to determine differences in pathogenic
fitness89. Aside from HIV-2 and HIV-1 group O viruses having the lowest fitness, HIV-1
subtype C was less fit than subtypes A, B, D and CRF01_AE89. Further competition
experiments showed that when HIV-1 subtype C was competed directly against other
dominant group M subtypes, it was at least 100-fold less fit82. These pairwise competitions
helped to reveal a general fitness order, where HIV-1 subtype B and D were slightly more
fit than subtype A and dramatically more fit than subtype C81.

Perhaps the most convincing form of evidence comes from a recent study by Venner and
colleagues90. Using a long-term natural history cohort of HIV-1 infected women in Uganda
and Zimbabwe, both in vivo and ex vivo estimates of pathogenic fitness for the different
HIV-1 group M isolates were determined. In Uganda, there are two dominating circulating
subtypes – subtypes A and D. In Zimbabwe, subtype C is the dominant group M strain.
Because of the subtype distribution in these different regions, generalizations about
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subtype fitness can be made for these different countries. Firstly, women infected with
subtype C were shown to have a slower rate of CD4+ T cell decline/week as opposed to
subtype D, with the highest rate of decline90. In reference to the country regions, these
results translate to women from Zimbabwe having a slower rate of decline compared to
those from Uganda. The 2-fold slower decline in Zimbabwean women in the absence of
disease translates to 2-5 years of longer asymptomatic disease. After grouping the women
into slow (stable CD4 counts above 350 and viral loads <2000 copies/ml in plasma for >3
years post-infection) and fast (CD4 decline to below 200 cells/ml within 2 years of
infection) progressors, no woman infected with subtype D was classified as slow
progressors in contrast to the 10% of women in this classification being infected with
subtype C90. The faster disease progression by HIV-1 subtype D was also confirmed by
studies examining cohorts in Brazil91 and in a separate study in East and Southern Africa92.
To take it further, Venner and his colleagues isolated the viruses from the cohort, PCR
amplified the env gene, and cloned it into pREC_nflNL4-3env. After producing these env
chimeric viruses, competition experiments against one of two subtype B env chimeric
viruses in PBMCs or primary CD4+ T cells were used to determine the relative replicative
fitness. Subtype D viruses could compete with the subtype B viruses whereas subtype A
viruses were less fit90. However, subtype C viruses were completely outcompeted by the
subtype B viruses and demonstrated low replicative fitness. Venner and his colleagues
concluded based on their findings that subtype C is less virulent in humans when compared
to subtypes A and D, with subtype D being the most virulent90. They discuss the possibility
of this playing a role in the disproportionate expansion and dominance of subtype C in the

15

global epidemic. With 2-5 more years of asymptomatic disease, HIV-1 subtype C may have
more opportunities for infection.

1.7 Subtypes and Transmission Fitness Differences
There is currently limited and conflicting observational evidence that investigates
transmission fitness differences between dominant HIV-1 group M subtypes. In a study
done in Rakai, Uganda, Kiwanuka and his colleagues identified 260 HIV-1 positive
discordant monogamous couples during a 5 year study period93. Since Uganda has two
dominating circulating subtypes, subtypes A and D, Kiwanuka and his colleagues could
attempt to discern whether or not there were differences in transmission efficiencies
between these two subtypes. For these couples, one partner was confirmed HIV-1+ and
they followed the HIV-1- partner until seroconversion and retroactively identified the
subtype between the couples. After adjusting for the appropriate variables, Kiwanuka and
colleagues found that subtype A viruses were associated with a higher rate of transmission
in comparison to subtype D viruses93. Although this suggests transmission differences
between subtypes may exist, it was limited in that other group M subtypes, such as subtype
C, was not investigated. Thus, for Kahle and colleagues they conducted a nested-case
control analysis using data from two prospective cohort studies of heterosexual HIV-1
discordant monogamous couples in Africa94; in this study, subtypes A, C, and D’s risk of
transmission was investigated. In this analysis, subtype C was not associated with increased
transmission risk in comparison to non-C subtypes94. Moreover, when subtype C was
compared to each of the subtypes individually, it was also not associated with an increased
transmission risk. Lastly, even when they compared transmission risk between subtypes A
and D, there were no significant differences. Altogether, the conflicting results of these two
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studies indicate that further studies need to be done to fully discern the presence or absence
of transmission fitness differences between the group M subtypes.

To date, only preliminary studies using the same pairwise competitions described earlier
have attempted to estimate the transmission fitness of the different dominant group M
subtypes. Initial studies showed subtype C to have relatively equal ability to replicate in
skin-derived Langerhans cell cultures compared to subtype B85. In an ex vivo assay that
utilized explanted genital tissue, HIV-1 subtype C could compete with, and sometimes
even win, against subtypes A and D isolates when examining replication in the tissue81.
However, when trans-infection experiments were performed downstream, subtype C was
outcompeted by the other subtypes. It is also important to note that consistent with previous
findings, this same study found that only R5 isolates could replicate in the tissue, whereas
X4 viruses could not55.

Altogether, these limited studies may suggest that subtype C has comparable transmission
efficiencies to other dominant group M subtypes even with a lower replicative ability. Here,
we tested whether acute HIV-1 subtype C viruses transmitted more efficiently in
comparison to acute subtypes A, B, and D using the ex vivo human explant assay. In this
study, eight env chimeric viruses that contain the pREC_nflNL4-3env backbone and the
envelope region from acute primary isolates were used. Using various mixtures of the
different subtype viruses, competition experiments were performed on both foreskin and
cervical explant tissue. In addition, competitions were performed on a T cell clone
permissive to HIV-1 infection (PM1) to assess the different subtypes’ replicative ability.
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1.8 Hypothesis and Aims
As discussed, what defines a virus’ ability to replicate in susceptible cells and cause
pathogenesis may be different than what defines its ability to transmit efficiently across the
genital mucosa. Although evidence shows that HIV-1 subtype C has the lowest replicative
fitness and causes the slowest disease progression, I hypothesize that HIV-1 subtype C will
have the highest transmission fitness and transmit the most efficiently in our ex vivo explant
model. To explore this hypothesis, we sought to 1) propagate and titre large volumes of
HIV-1 chimeras that contain the envelope from subtypes A-D acute primary viruses; 2)
compete these viruses in round robin on cervical and foreskin explant tissue; 3) assess the
ability of the different subtypes to replicate in the tissue and be transported out of the tissue
by migrating cells for replication in susceptible T cells; and 4) compare the transmission
fitness of the subtypes to their abilities to replicate directly on PM1 cells. The work
presented here will help provide insight into whether or not there are differences in
transmission efficiencies between the dominant HIV-1 group M subtypes and the
relationship to their abilities to cause pathogenesis.
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Chapter 2: Materials and Methods
2.1 Cells
U87.CD4.CCR5 cells were obtained from the NIH AIDS Reagent Program.
U87.CD4.CCR5 cells were the cell types used to propagate large amounts of virus. These
cells are human glioblastoma cells that express both receptors required for sexual
transmission of HIV-1. These cells were chosen for propagation because they are easily
infectable and exhibit syncytia when infected. U87.CD4.CCR5 cells were cultured in 10%
FBS-DMEM supplemented in 1% penicillin/streptomycin, 300 g/mL G418, and 1 g/mL
puromycin (DMEM complete). G418 selects for cells expressing CD4 and puromycin
selects for cells expressing CCR5.

For trans-infection studies in the explant model and replicative fitness experiments, PM1
cells were used. PM1 cells are a clonal derivative of HUT 78, a cutaneous T lymphocyte.
These cells are permissive for growth of macrophage and T cell tropic viruses, such as
HIV-1. PM1 cells were obtained from the NIH AIDS Reagent Program and cultured with
10% FBS-RPMI supplemented with 1% penicillin/streptomycin (RPMI complete).

2.2 Virus Cloning and Propagation
A complete list of viruses used in this study can be found in Table 1. Acute primary subtype
B viruses were obtained from the Center for HIV/AIDS Vaccine Immunology (CHAVI)
acute infection studies. The study initiated in June 2006 and ended in June 2013. During
this time, group 1 participants characterized by people with acute HIV infection began
enrolling and blood collection occurred. Primary subtype A, C, and D viruses were
obtained from women enrolled in the Hormonal Contraception and Risk of HIV
19

Acquisition Study in Uganda and Zimbabwe95. Upon primary HIV-1 infection, women
were enrolled into a subsequent study, the Hormonal Contraception and HIV-1 Genital
Shedding and Disease Progression among Women with Primary HIV Infection (GS)
Study96–98 (Table 1). Blood and cervical samples were collected every month for the first
six months, then every three months for the first two years, and then every six months up
to 9.5 years. DNA was extracted from patient’s PBMC samples obtained at the
seroconversion visit and every three months post HIV infection. The entire gp120 coding
region and extracellular domain of gp41 (referred to as env DNA) was PCR amplified from
PBMC DNA derived from the seroconversion visit for subtypes A, C, and D. The same
amplification procedure was done for subtype B viruses obtained from group 1 of the
CHAVI acute infection studies. This was done to ensure as close of a representation to the
transmitted/founder (T/F) virus.

All HIV-1 env genes from acute infection samples were cloned and propagated using a
protocol previously described99 (Figure 3). HIV-1 env was the region of interest due to
studies showing its role in sexual transmission of HIV-1 and defining characteristics of the
T/F virus72–74. The HIV-1 env gene was cloned into pREC_nflNL4-3env/URA3 using yeast
recombination/gap repair. Positive colonies signified successful recombination as colonies
did not survive with the uracil gene still present in the vector. The pREC_nfl construct
containing the HIV-1 env from acute infection samples was co-transfected into 293T cells
together with a complimenting vector pCMV_cplt to produce fully infectious particles. My
work relevant to this research project started here, where I expanded virus quantities for
downstream assays. To do this, I infected U87.CD4.CCR5 and harvested virus after 3, 7,
10, and 14 days of culture.
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Table 1. Acute env chimeric viruses used in this study
VIRUS

PARTICIPANT

INFECTION

SEX

TRANSMISSION

PHENOTYPE

SUBTYPE

ID

DESIGNATION

GROUP

63UR

GS-0221-03

Acute

F

Heterosexual

R5

A

15U

GS-0054-07

Acute

F

Heterosexual

R5

A

13U

GS-0043-07

Acute

F

Heterosexual

R5

A

B4

WEAUd15.410.

Acute

M

MSM

X4/R5

B

Acute

M

Heterosexual

R5

B

787
B7

SC05.8C11.234
4

23Z

GS2003

Acute

F

Heterosexual

R5

C

6Z

GS2182

Acute

F

Heterosexual

R5

C

14U

GS-0048-07

Acute

F

Heterosexual

R5

D
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CCR5

Figure 3. Schematic of PCR amplification of HIV-1 env and cloning into pREC_nflNL43env/URA3

(courtesy of Dr. Eric Arts)

The entire gp120 coding region and extracellular domain of gp41 (termed env DNA) was
PCR amplified from DNA derived from PBMCs isolated during the seroconversion visit
and acute infection. This env product was cloned into pREC_nflNL4-3env/URA3 via yeast
recombination/gap repair. After isolating the new pREC_nfl vector containing env from
patient DNA, it was co-transfected with a complementing vector in 293T cells to produce
fully infectious viral particles. Subsequent viral propagation was performed in
U87.CD4.CCR5 cells.
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2.3 Virus Quantification
Median tissue culture infectious dose (TCID50) was determined for each virus in Table 1.
TCID50 values are a measure of infectious titre and quantifies the amount of virus required
to kill or produce a cytopathic effect in 50% of inoculated tissue culture cells. Quantifying
the titres of the propagated viral stocks were needed for infection in the explant assay. Ten
thousand U87.CD4.R5 cells were seeded on a 96 well plate for virus infection (4
viruses/plate). The following day, cells were infected, in triplicate, with virus stocks from
day 7 harvests that were serially diluted from neat to 1:107 (Figure 4). Reverse
transcriptase (RT) activity of the supernatant of infected cells were used to calculate
TCID50 values of the viruses using the Reed-Muench Method100,101. This method calculates
the number of infected cells observed to TCID50 values.

RT activity was determined using the well-established radioactive RT assay on the
supernatant of infected U87.CD4.R5 cells102,103. Briefly, 10uL of supernatant from the
infected cells was mixed with 20uL of RT master mix [50mM Tris-HCl (pH 7.8), 75mM
KCl, 2mM dithiothreitol, 5 mM MgCl2, 5ug of poly(rA)-poly(dT) per ml, 0.5% (vol/vol)
NP-40, 1uL of fresh 10-mCi/ml[-32P]TTP per ml]. The RT master mix lysed the virus but
maintained functionality of the RT and supplied radioactive nucleotides. Thus, any
functional RT from the virus will make new DNA with radioactive nucleotides
incorporated. This radioactivity can then be imaged on a screen.

After incubation for 2 hrs at 37C, the samples were blotted onto a diethylaminoethyl
cellulose (DEAE-C) filter mat. The positively charged diethylaminoethyl groups can bind
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the negatively charged DNA. The filters were allowed to dry, washed with a saline-sodium
citrate (SSC) buffer (0.15M NaCl, 0.015M sodium citrate) five times, rinsed two times
with 80% ethanol, and dried once more. The filters were then placed in a phosphor screen
overnight to expose the screen to the radiation from RT-produced DNA. The next day, it
was imaged with Storm 820 Phosphorimager to scan the phosphor screens for positive
signals. These positive signals represent RT activity and were used to calculate TCID50
values.

2.4 RNA Extraction and RT-PCR for DNA Sequencing and Subtyping
In order to confirm the subtype of the different viruses used, RNA from the propagated
viral stocks were extracted for subsequent RT-PCR. RNA extraction was performed using
the QIAGEN RNeasy Mini kit as per manufacturer’s instructions and eluted in RNA-free,
DNA-free H20 (sigma H20). QIAGEN’s One-Step RT-PCR Enzyme mix and primers
specific to the gp120 region (ENVB, ED14) were used to perform first round RT-PCR
(Table 2). Ampure XP Beads were used to purify the cDNA product with subsequent
second round PCR amplification using 2X KAPA HiFi HotStart Ready Mix and primers
specific to the C2-V3 env region (E80, E125). PCR cycle conditions for the 1st round were
50°C for 30min, 95°C for 15 min, followed by 35 cycles of 94°C for 30s, 55°C for 30s and
72°C for 90s, and a final extension of 72°C for 10min. The PCR conditions for the 2nd
round were 95°C for 3 min, followed by 25 cycles of 95°C for 30s, 55°C for 30s and 72°C
for 30s, and a final extension of 72°C for 10min. Each C2-V3 env sequence was
phylogenetically aligned with a set of reference subtype A, B, C, and D viruses obtained
from Los Alamos National Laboratory’s HIV sequence database14, trees were constructed
via Muscle and maximum likelihood methods in MEGA X104.
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Figure 4. Example of RT Assay protocol, quantifying four viruses
Ten thousand U87.CD4.CCR5 cells were seeded on 96 well plate on day 0. On day 1, viral
stocks were titrated and cells were infected in triplicate, as shown. Reverse transcriptase
activity measured in the supernatant was used to calculated TCID50 values of the viruses
using the Reed-Muench Method.
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Table 2. DNA Primers used in this study
PRIMERS

PRIMER SEQUENCE (5’ → 3’)

ENVB

AGAAAGAGCAGAAGACAGTGGCAATGA

ED14

TCTTGCCTGGAGCTGTTTGATGCCCCAGAC

E80 W/ ILLUMINA TAG

TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCAATTCCCATACATT
ATTGTG

E125 W/ ILLUMINA TAG

GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCAATTTCTGGGTCCC
CTCCTGAGG

GAG-CONS1

GAGAGAGATGGGTGCGAGAGCG (HXB2 783-804)

UNIV-GA4

TTGCCAAAGAGTGACCTGAGGGAA (HXB2 2250-2273)

GSCA F

CATGTTTTCAGCATTATCAGAAGGA (HXB2 1299-1323)

GSCA R

TGCTTGATGTCCCCCCACT (HXB2 1359-1377)

GSCA PROBE

6-Fam-TACTGGGACAGCTACAACCATCCCTT-BHQ (HXB2 968-993)

*Illumina Tag
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2.5 Ex vivo Tissue Explant Assay
Explanted genital tissue was used to assess the relative transmission fitness of the viruses
listed in Table 1. Cervical tissue was obtained from the National Disease Research
Interchange (NDRI) tissue bank in Philadelphia, USA105. NDRI collects tissues from over
two hundred sites under rigorous reviews and strict government regulations; ethical
approval, consent forms, and patient data are kept at their site. Anonymously donated
foreskin tissue was obtained from adult men (>18) undergoing elective circumcision (for
cosmetic or cultural reasons) at the University Urology Associates (UUA) clinic in Toronto.
Viruses in Table 1 were combined and used to infect genital explant tissue in “competitions”
to assess relative transmission fitness (Figure 5). Each of the eight competitions consisted
of 4 different viruses, where each virus was eventually competed with all others through a
round-robin design (Table 3). In this assay, when a given virus gets the opportunity to
establish infection it will take over and outcompete all the other viruses. Consequently, if
all eight viruses were competed against each other at once, the ability to elucidate a relative
transmission fitness order would not be possible and thus, a round-robin design is used.
Additionally, four competitions from Table 3 (5-8) excluded subtype D. Due to the
dominance of subtype D in my results, it was removed to attempt to discern the relative
transmission fitness differences of the other subtypes.
Genital tissue was cut into ~3 mm3 blocks, placing three pieces of tissue per well in a 48well flat-bottom plate. Tissue was suspended in 10%FBS-RPMI complete media and
exposed to a mixture of viruses at either a multiplicity of infection (MOI) of 0.01 each (150
infectious units, IU) or 5x this (MOI 0.05; 750IU) for 6 hours (Table 3). Each competition
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was performed in duplicate for each donor. After this, the inoculating mixture was
discarded and tissue was washed twice with 250uL of PBS to remove any input virus.
Subsequently, tissue was cultured in 10%FBS-RPMI complete media for 24 hours in the
same well.

Tissue pieces were then removed with sterile forceps, washed once with 250uL of PBS,
and placed in one well of a 96-well U-bottom plate and cultured in 10%FBS-RPM1
complete media supplemented with Normocin (anti-fungal) for 10 days. After removal of
the tissue, migratory cells (MC) emigrating from the tissue were harvested. To do this,
culture media was removed from the wells and placed into a 1.5mL Eppendorf tube. After
tubes were spun at 1500g for 5min, the liquid was decanted and 250uL of PBS was added
to the tube. This spin-wash step was repeated once more with a final decanting step. A
small pellet was observed frequently. Forty thousand PM1 cells were then seeded per well
in a 96-well U-bottom plate. The pellet in the Eppendorf tube was resuspended and cocultured with the PM1 cells in 10%FBS-RPMI complete media for 10 days. For tissue
culture and migratory cell/PM1 co-cultures, media was changed every 3 days.
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Figure 5. Experimental protocol for the ex vivo explant assay
Three ~3 mm3 pieces of cervical or foreskin tissue were infected with a mixture of viruses
in Table 3 for 6 hours. After washing the tissue thoroughly to ensure input viruses were
removed, tissue was cultured for 24 hours. Following this 24 hour culture, migratory cells
were collected from the supernatant and co-cultured with a clonal T cell line, PM1, for 10
days. Concurrently, tissue was cultured for the same amount of time.
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Table 3. Acute env chimeric viruses included in each competition
COMPETITION

VIRUSES

1/A

15U x B4 x 6Z x 14U

2/B

15U x B7 x 23Z x 14U

3/C

63U x B4 x 6Z x 14U

4/D

63U x B7 x 23Z x 14U

5/E

15U x B4 x 23Z x 13U

6/F

15U x B7 x 6Z x 13U

7/G

63U x B4 x 23Z x 13U

8/H

63U x B7 x 6Z x 13U
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2.6 Direct Competitions on PM1 cells
To assess the relative replicative fitness of the different subtypes, the same competitions in
Table 3 were directly exposed on PM1 cells. Forty thousand PM1 cells were seeded per
well in a 96-well U-bottom plate in 10%FBS-RPMI complete media. PM1 cells were
subsequently infected with 200 IU of each virus (MOI 0.005) for 3 hours and after this time
the supernatant was removed and 250uL of new media was added. This was cultured
concurrently with the explant assay for 10 days and media was changed every 3 days during
this time.

2.7 DNA Extraction and PCR Amplification
After the 10 day culture of both tissue and MC/PM1s, the explant assay was completed. At
completion of the assay, tissue, MC/PM1 co-cultures, and PM1 cells were lysed and DNA
extracted with either the QIAGEN DNeasy Blood and Tissue, or the 96-well format of the
kit, QIAGEN DNeasy 96 Blood and Tissue Kit, both as per manufacturer’s instructions.
Briefly, tissue was lysed overnight with the provided Proteinase K solution at 56C;
MC/PM1 co-cultures and PM1 cells were lysed with the Proteinase K solution for 10 min
at 56C. After lysis, the lysate was passed through the DNeasy Mini Spin Column or plate.
The DNA was then spin-washed with the provided buffers in two steps and then eluted in
sigma H20.

Two rounds of PCR amplification were performed with primers specific to the C2-V3 env
region (Table 2). A set of external primers, ENVB and ED14, were used for the first round
of amplification (gp120-coding region of env, ~1.7kb). This was followed by a set of nested
primers, E80 and E125 w/ Illumina tag, which was used for the second round of
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amplification (C2-V3 env region, 0.48 kb) (Figure 6). PCRs contained 0.2 µM of each
primer, 1.5 mM MgCl2, 5x Platinum Taq PCR buffer, 0.2 mM dNTPs and 2 units Platinum
Taq DNA polymerase. The amount of template for the external and nested PCR was 20uL
and 5uL, respectively. PCR cycle conditions were 95°C for 2min, followed by 35 cycles
of 95°C for 30s, 55°C for 30s and 72°C for 2min (external) or 45s (nested), and a final
extension of 72°C for 10min. Successfully amplified PCR products were confirmed on a
1% agarose gel to verify product size of 480 bp. Samples that did not PCR amplify were
repeated twice.
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Figure 6. PCR strategy for Next-Generation Sequencing
The C2-V3 env region was PCR amplified in two rounds for subsequent NGS analyses.
The first round produced a 1.70 kb product with the final product being the C2-V3 env
region - 0.48 kb of gp120.
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2.8 Next-Generation Sequencing Library Preparation and Sequencing
To perform next-generation sequencing on the PCR amplicons, the sequences need to be
tagged with a barcode and combined and pooled in equivalent amounts (Figure 7).
Purification of the successfully amplified PCR amplicons and normalization of their
concentrations was performed using SequalPrepTM Normalization Plate Kit, as per the
manufacturer’s instructions. This plate utilizes ChargeSwitch Technology that allowed a
switchable surface charge depending on the pH of the surrounding buffer. This allowed for
purification, binding of ~25ng of DNA, and elution at a certain concentration. In a three
step process, PCR amplicons were bound to the plate after a 1 hour incubation,
subsequently washed, and then eluted in water to achieve an expected DNA concentration
of 1-2 ng/ul.
Illumina’s Nextera XT DNA Library Preparation Kit was used to prepare up to 384 purified
and normalized PCR amplicons at one time. Using a one-step process called tagmentation,
the DNA is simultaneously fragmented and tagged with an adaptor sequence. A limited
PCR cycle then used the adapters as primers to amplify the tagged DNA while adding index
adaptor sequences to both ends; this allowed for pooling of the library (Figure 7). After
this, normalization and purification with SequalPrep was performed once more.
Sequencing was performed by Illumina’s MiSeq System at the London Regional Genomics
Centre at the Robarts Research Institute at Western University. The samples were
sequenced using the MiSeq 600 cycle Reagent Kit v3, which extends read lengths up to 2
x 300 bp. The sequences were then analyzed by Illumina’s Metagenomics app, BaseSpace.
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Simply, this app automatically converts the sequence data to FASTQ format and provides
the user with a multitude of genomic analysis apps.
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Figure 7. NGS preparation and sequence analysis pipeline
After PCR amplification, sequences were re-amplified with different barcode sets
according to their respective assay compartments (tissue vs. MC/PM1). After this, all
sequences were pooled and sequenced using MiSeq. SeekDeep (Hathaway et al, 2012), a
pipeline to determine haplotype frequencies was employed on the sequences.
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2.9 Sequence and Statistical Analysis
Sequence data was analyzed by Dr. Jeff Bailey’s group at Brown University using their
SeekDeep pipeline106. This open source pipeline allows for haplotype frequency estimation
on targeted sequencing data for multiple samples in a population. In this case, the haplotype
in question is the C2-V3 env region of a given virus. Briefly, their pipeline demultiplexes
on the samples, clusters and collapses unique reads, and undergoes final filtering and
alignment of the population to sequences of the known input viruses to give a relative
abundance of each virus sequence in each competition as a proportion of 100 (Figure 7).

Subtype comparisons were performed by averaging relative abundance from the technical
replicates of each virus and then taking the average of those averages for all the viruses in
a single subtype. For example, in competition 1 (Table 3) the relative abundance of virus
15U was averaged across its technical replicates. After this was done for every single virus
in every competition, the relative abundance of 63U, 13U, and 15U, all the subtype A
viruses employed in this study, were averaged across all a) competitions that included all
subtypes (1-4); and b) competitions that excluded subtype D (5-8). This allowed the
comparison of the average relative abundance of subtype A, in comparison to the other
subtypes, across all a) competitions that included all subtypes; and b) competitions that
excluded subtype D. Means values with SEM are presented.

2.10 Quantitative Polymerase Chain Reaction (qPCR)
In a 50uL reaction, an external PCR was initially completed using primers gag-cons1 and
UNIV-GA4 (Table 2). Following this PCR, 5uL of the PCR product was added to the
TaqMan Fast Advanced Master Mix in addition to primers gsca F, gsca R, gsca probe.
37

Samples were run using the QuantStudio5 Real-time PCR system under the following
reaction conditions: 60oC for 2min, 95oC for 20s, 40 cycles of 95oC for 1s and 60oC for
43s. All samples were run in duplicate. Samples were considered negative when CT values
were above 35.

38

Chapter 3: Results
3.1 Virus Quantification and Titres
Acute env chimeric viruses were previously generated by past members of the Arts Lab90.
To ensure equal opportunity for infection in the explant assay for all viruses utilized, viral
stocks were titred on U87.CD4.CCR5 cells using the standard TCID50 method after largescale propagation. Phosphor images displayed the number of positive signals per row of
triplicate as dilutions increased 10-fold per row going down (Figure 8). The first row of
each virus frequently did not have any positive signal, most likely due to cytopathic effects
of infection. Using the Reed-Muench Method, viral titres were quantified (Table 4). Virus
63U had the highest titre of 2.18 x 106 IU/mL and 14U had the lowest titre of 1.03 x 103
IU/mL. Due to 14U’s low titre, larger volumes of this virus were utilized for the
competition experiments. As such, propagation of 14U was done more than once which
meant an additional RT assay needed to be performed.
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Positive

Negative
Neat
1:10
1:102
1:103
1:104
1:105

B

A

6

1:10

1:107

63

15

B4

B7

23Z

6Z

13

14

Figure 8. Phosphor Images produced from RT assay of each virus used in the study
Each row of three corresponds to one dilution factor with the top row being the most
concentrated and the last row being the least concentrated. The top row frequently
showed no positive signals due to high concentration of virus. Day seven harvests of
each virus were used. (A) Lighter signals did not count as positive when compared to
intensity of signals in the upper rows. (B) An example of one positive signal in a row
with two negative signals.
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Table 4. Viral titres calculated using the Reed-Muench Method, corresponding to
positive signals in phosphor images
VIRUS

TITRE (IU/ML)

63U

2,181,971.59

15U

122,701.279

B4

1,227,012.79

B7

218,197.159

23Z

122,701.278

6Z

218,197.159

13U

218,197.159

14U*

1035.904; 1851.06

*two different propagations
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3.2 Subtype Confirmation
To confirm that the viral stocks used for propagation belonged to the expected subtype,
RT-PCR was performed on propagated virus with subsequent phylogenetic analysis. Using
reference sequences from Los Alamos National Laboratory’s HIV sequence database, the
C2-V3 env region of the different subtype chimeric viruses were aligned with those from
the sequence database. As expected, phylogenetic analysis demonstrated the presence of
three HIV subtype A (63U, 15U, 13U), two subtype B (B4, B7), two subtype C (23Z, 6Z),
and one subtype D (14U) virus (Figure 9).
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Figure 9. Phylogenetic alignment for subtype identification of each env chimeric
virus
Reference HIV-1 sequences were obtained from Los Alamos National Laboratory’s
HIV sequence database and aligned with the C2-V3 env region from the viruses used
in this study. Maximum likelihood tree was generated via MEGA X. Open shapes
represent the reference sequences and filled-in shapes represent the viruses used in
this study. Blue = Subtype A, Yellow = Subtype B, Red = Subtype C, and Green =
Subtype D.
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3.3 Direct Competitions on PM1 cells to Assess Replicative Fitness
To understand whether transmission fitness may be different than replicative fitness, the
competitions in Table 3 were performed directly on PM1 cells. As discussed, the
replicative or pathogenic fitness of a virus strain can be defined as the relative ex vivo
replication capacity of HIV-1 in CD4+ T cells and/or PBMCs82,83. Thus, forty thousand
PM1 cells were infected with 200 IU of each virus (MOI 0.005) for 3 hours and cultured
concurrently with the explant assay for 10 days.

Figure 10 provides a summary figure that mirrors the same analysis done for transmission
fitness. Subtype D was the most effective at replicating in PM1 cells, at around 80%, with
subtype B consisting of almost 20% of viral replication. Subtypes A and C were
outcompeted by subtypes B and D, with very low levels of replication measured in PM1
cells. When subtype D was removed from the competition, there was no observed
differences in the replication of the different subtypes.

Figure 11 provides the same data as Figure 10, but showing the results of each individual
competition with viruses grouped by subtype (competitions performed in duplicate,
average of replicates shown). Panels E-H, the four competitions that excluded subtype D,
showed inconsistent results with which subtype replicated more effectively. Competitions
5 and 8 (Panels E and H) showed subtype C to be the most effective, while competitions 6
and 7 (panels F and G) had subtype A as the “winner”. Subtype B never outcompeted both
subtypes, outcompeting only subtype A in panels E and H and only subtype C in panel F.
As such, drawing conclusions from summary figure 10B is challenging.
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Figure 10. Average relative abundance of each subtype in PM1 cells
40,000 PM1 cells were infected with 200 IU of each virus for a MOI of 0.005. After 3 hour
infection, cells were cultured concurrently with the explant assay for 10 days. Competitions
were performed in duplicate. The average relative abundance of each across all eight
competitions are presented. (A) Competitions including all four subtypes; (B) competitions
excluding subtype D. Mean values with SEM are shown.
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Figure 11. Individual multi-virus competitions performed on PM1 cells, grouped by
subtypes
(A-H) 40,000 PM1 cells were infected with different mixtures of env chimeric viruses as
shown below the graphs. Competitions were performed in duplicate. The average relative
abundance of each subtype in each specific competition in PM1 cells are presented. Mean
values with SEM are shown.
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3.4 Multi-virus Competitions in Human Explant Tissue to Assess Relative
Transmission Fitness
Three tissue pieces (each ~3mm3) from cervical tissue were exposed to different mixtures
of four acute env chimeric viruses. To simulate trans-infection events, after 24 hours the
migratory cells were isolated and co-cultured with PM1 cells. At the end of the 10 day
culture period, both compartments were lysed, proviral DNA was extracted, and sequences
were PCR amplified and sequenced for alignment and counting via SeekDeep106. It is
important to note that although the tissue is washed well after initial viral inoculation, HIV1 proviral DNA instead of HIV-1 RNA is extracted to further ensure the measuring of
infection instead of residual inoculating virus.

Each of the eight competitions consisted of 4 different viruses, where each virus was
eventually competed with all others through a round-robin design. Many studies from our
group have observed a phenomenon where one virus in a mixture will take over and
outcompete all the other viruses, in this assay. Consequently, if all eight viruses were
competed together at once, the ability to elucidate a relative transmission fitness order
would not be possible and thus a round-robin design is used. Four competitions (1-4, Table
3) included one of each subtype A, B, C, and D, while the four remaining competitions (58, Table 3) did not include a subtype D virus. Once again, competitions excluding subtype
D were performed in light of the fact that it outcompeted all the other viruses. The
combinations of viruses ensured that each virus was competed against all the other viruses
in two different mixtures. For example, competition 4 has a mixture of 63U, B7, 23Z, and
14U and competition 8 also competes 63U and B7 against one another but in the presence
of 13U and 6Z.
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3.4.1 Using a low MOI may result in stochastic infection events that do
not reflect differences in transmission fitness between subtypes
A multiplicity of infection (MOI) of 0.01 was initially used based on previous published
studies in our group107. Briefly, in an explant of ~3mm3 there are approximately 5000
migratory cells107. Thus, in an infection of three explant pieces there are ~15,000 migratory
cells. With 150 IU of each virus added to the inoculating mixture, results using an MOI of
0.01 are summarized in Figures 12 and 13. The summaries compared the average relative
abundance of each subtype, which is assumed to represent the average relative replication
of each subtype, in both tissue and MC/PM1 co-cultures. Figure 12 provides the average
relative abundance across all eight competitions, separating the competitions that included
subtype D virus 14U (Panel A) and those that did not (Panel B). Figure 13 provides the
same data as Figure 12, but showing the results of each individual competition, stratified
by tissue donors (viruses of same subtype grouped).

Overall, the PCR efficiency from these competitions were very low (Figure 14A); an
overall PCR efficiency of ~45-50% was measured. PCR efficiency was measured by the
number of samples with amplified PCR products over the total number of samples. This
was done to illustrate what I speculate as stochastic infection events. The PCR inefficiency
of these competitions are also demonstrated in Figure 13, where some competitions did
not have any measurable HIV-1 replication in the tissue and/or replication in MC/PM1 cocultures (Panels B and E-H). Moreover, there was inconsistency when comparing the
“winner” of the competitions between donors and between competitions. For example, in
competition 4 (Panel D) there was higher replication of subtype B in donor A vs. subtype
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A in donor B in MC/PM1 co-cultures. Additionally, in competitions 1 and 4 (Panels A &
D) subtype C and D had equal levels of replication in donor A MC/PM1 co-cultures vs.
subtype B being the “winner” in donor A MC/PM1 co-cultures. Overall, there was concern
that any of the trends exhibited in Figure 12 were due to stochastic events based upon the
low PCR efficiency (Figure 14) and the inconsistency of results in Figure 13. To address
the possibility of stochastic infection events, the infectious units per virus was increased to
5x the original amount. Therefore, for the eight virus competitions previously performed
the infectious units per virus in each mixture was increased to 750 IU instead of 150 IU.
With this increased MOI, the absolute abundance of integrated HIV-1 DNA in tissues (both
cervix and foreskin, measured by qPCR) increased by 1.65-fold (Figure 15). Moreover,
the PCR efficiency improved (Figure 14B) with an overall efficiency of 85-90%.
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Figure 12. Average relative abundance of each subtype in cervical tissue and from
migratory cells after infection at 0.01MOI
(A) Cervical tissue was dissected into ~3mm3 explants and exposed to mixtures of 4
different env chimeric viruses at 150 IU each (repeated in n=2 tissue donors; 2 technical
replicates of tissue and 2 of MC/PM1 per competition). The average relative abundance for
each subtype is presented in tissue and MC/PM1 co-cultures. (A) Competitions including
all four subtypes; (B) competitions excluding subtype D. Mean values with SEM are shown.
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Figure 13. Individual multi-virus competitions using cervical tissue at 0.01 MOI,
grouped by subtype.
(A-H) Cervical tissue (n=2) was dissected into ~3mm3 explants and exposed to mixtures
of 4 different env chimeric viruses as shown below the graphs. Competitions were
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performed in duplicate. The average relative abundance for each subtype in each specific
competition for cervical tissue and MC/PM1 co-cultures are presented.
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A

500bp

B

500bp

Figure 14. Two representative electrophoresis gels to demonstrate PCR efficiencies
(A) 1% agarose gels were used to determine the presence of C2-V3 env product at
~500bp. At 0.01 MOI, PCR efficiencies were low: out of 16 samples only 4 were
positive. 100bp DNA ladder was used. (B) At 0.05 MOI, PCR efficiencies increased:
out of 8 samples 5 were positive. 1kb DNA ladder used.
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Figure 15. Comparison of absolute quantity of integrated HIV DNA in tissue between
MOI conditions
Cervical tissue (n=2) exposed to 150IU or cervical (n=1) and foreskin (n=1) tissue exposed
to 750IU of each virus were harvested after 10 days, tissue was lysed and total HIV-1 copy
number between the two MOI conditions was assessed using a gag-specific qPCR. Mean
with SEM values are shown.
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3.4.2 Subtype Transmission Fitness Differences in Cervical Tissue
Figure 16 provides a summary that compares the average relative abundance of each
subtype across all the competitions in cervical tissue, separating the same competitions that
included all subtypes (Panel A) and those that did not include subtype D (Panel B). Figure
17 provides the same data as Figure 15, but showing the results of each individual
competition with viruses grouped by subtype (competitions performed in duplicate,
average of replicates shown). The number of competitions with at least one replicate having
an identified target sequence increased. Viral replication was not measured in only two
competitions at 0.05 MOI in cervical tissue (Figure 17E,G) when compared to 5/8
competitions that did not measure viral replication in either tissue or MC/PM1 co-cultures
at the 0.01 MOI (Figures 13B, E-H). The increased PCR efficiency coupled with the
increased number of competitions with measurable viral replication provided more
confidence that the trends exhibited in Figure 16 were not due to stochastic infection
events. Therefore at this MOI, the relative transmission fitness differences between the
subtypes were evaluated.

When all four dominant group M subtypes were competed against each other, all the other
subtypes were outcompeted by subtype D in the tissue except for subtype A, which had
approximately 12.5% replication in the tissue (being observed in one replicate of one
competition). Not only was there a high level of subtype D replication in the tissue, only
subtype D was pulled through the tissue by MCs for replication in PM1 cells. Therefore,
despite subtype D accounting for only 25% of the inoculating mixture, it was present in
greater than 85% of replicating virus in the tissue and 100% of the virus being transmitted
out of the tissue for replication in PM1 cells.
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Due to the fact that subtype D virus 14U took over viral replication in the tissue and
MC/PM1 co-cultures, transmission fitness differences between the other subtypes could
not be discerned. Therefore, subtype D was eliminated from a subset of competitions to
attempt to investigate the relative transmission fitness of the other subtypes. In the absence
of subtype D virus, we observed trend differences in the transmission of subtypes A-C in
cervical tissue (Figure 16B). Subtype C viruses had the highest level of replication in tissue
compared to the other subtypes but were pulled through the tissue by MCs to replicate in
PM1 cells the least efficiently. Subtype B viruses did not replicate in the tissue at all, but
had the highest level of replication in MC/PM1 co-cultures; similarly, subtype A viruses
had very low levels of replication in the tissue but had higher levels of replication than
subtype C in MC/PM1 co-cultures.
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Figure 16. Average relative abundance of each subtype in cervical tissue and from
migratory cells after infection at 0.05 MOI
Cervical tissue (n=1) was dissected into ~3mm3 explants and exposed to mixtures of 4
different env chimeric viruses at 750 IU each. The average relative abundance of each
subtype across all eight competitions in tissue and MC/PM1 co-cultures are presented.
Each competition was done in done in duplicate. (A) Competitions including all four
subtypes; (B) competitions excluding subtype D virus. Mean values with SEM are shown.
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Figure 17. Individual multi-virus competitions using cervical tissue at 0.05 MOI,
grouped by subtype
(A-H) Cervical explant tissue (n=1) was exposed to mixtures of 4 different env chimeric
viruses as shown below the graphs. Competitions were performed in duplicate. The average
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relative abundance for each subtype in each specific competition for tissue and MC/PM1
co-cultures are presented.
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3.4.3 Subtype Transmission Fitness Differences in Foreskin Tissue
Trends in relative transmission fitness of HIV-1 subtypes were different in the foreskin
compared to the cervix (Figure 18). Similarly to the cervix, subtype D once again
outcompeted the other subtypes in the tissue. There was low levels of replication of
subtypes B and C but no subtype A replication in the tissue. However, in contrast to the
cervix, subtype B (as opposed to D) was pulled through foreskin tissue by MC’s to infect
PM1 cells the most efficiently. Subtype D accounted for only 25% of virus replication in
the MC/PM1 co-cultures.

When foreskin tissue is infected with different subtypes in the absence of subtype D
(Figure 18B), subtype B and C had equal levels of replication, ~43%, and subtype A had
the lowest, at 7%. However, only subtype B viruses were observed in MC/PM1 co-cultures.

Figure 19 provides the same data as Figure 18, but showing the results of each individual
competition with viruses grouped by subtype (competitions performed in duplicate,
average of replicates shown). Unlike cervical tissue, viral replication was measured in both
compartments in at least one replicate for all competitions performed in foreskin tissue.
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Figure 18. Average relative abundance of each subtype in foreskin tissue and from
migratory cells after infection at 0.05 MOI
Foreskin tissue (n=1) was dissected into ~3mm3 explants and exposed to mixtures of 4
different env chimeric viruses at 750 IU each. The average relative abundance of each
subtype across all eight competitions in tissue and MC/PM1 co-cultures are presented.
Each competition was done in duplicate. (A) Competitions including all four subtypes; (B)
competitions excluding subtype D virus. Mean values with SEM are shown.
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Figure 19. Individual multi-virus competitions using foreskin tissue at 0.05 MOI,
grouped by subtype
(A-H) Foreskin explant tissue (n=1) was exposed to mixtures of 4 different env chimeric
viruses as shown below the graphs. Competitions were performed in duplicate. The average
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relative abundance for each subtype in each specific competition for tissue and MC/PM1
co-cultures are presented.
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3.5 Relative Abundance of each Individual Virus in Cervical and
Foreskin Tissue
In summary, in cervical tissue the trends suggest that subtype D is the most effective at
replicating in the tissue and being pulled through by MCs for replication in PM1 cells.
Once subtype D is removed, the trends suggest that subtype B is pulled through the tissue
the most efficiently, followed by subtypes A and C, respectively. This trend was observed
despite the fact that subtype C replicated in the tissue the most effectively.

When viruses from all four subtypes were competed against one another, subtype A virus
15U and subtype D virus 14U were solely responsible for the trends stated above (Figure
20A). These specific viruses drove the trends that suggest subtype D replicates in the tissue
and MC/PM1 co-cultures the most effectively.

In the absence of subtype D, the relative transmission of subtypes B and C were driven by
one virus of each subtype (Figure 20B). Viruses B4 and 6Z were solely responsible for
the trends observed for subtypes B and C, respectively. Two viruses, 63U and 13U, were
responsible for the trends observed for subtype A, and there was no measured replication
of virus 15U in MC/PM1 co-cultures. Subtype C virus 6Z outcompeted the other viruses
in the tissue.

In foreskin tissue, the trends suggest that subtype D is the most effective at replicating in
the tissue but subtype B is the most effective at replicating in MC/PM1 co-cultures, even
in the presence of subtype D. We observed in all eight competitions the relative
transmission of subtype B was driven by both B4 and B7 (Figure 21A,B). Otherwise, any
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replication observed for the other subtypes A, C, and D, were driven by one virus
respectively: 13U, 6Z, and 14U (Figure 21A,B).
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Figure 20. Average relative abundance of each individual virus in cervical tissue at 0.05
MOI
Cervical tissue (n=1) was dissected into ~3mm3 explants and exposed to mixtures of 4
different env chimeric viruses at 750 IU each. The average relative abundance for each
specific virus across all eight competitions in tissue and MC/PM1 co-cultures are presented.
Each competition was done in done in duplicate. (A) Competitions including all four
subtypes; (B) competitions excluding subtype D. Mean values with SEM are shown.
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Figure 21. Average relative abundance of each individual virus in foreskin tissue at 0.05
MOI
Foreskin tissue (n=1) was dissected into ~3mm3 explants and exposed to mixtures of 4
different env chimeric viruses at 750 IU each. The average relative abundance for each
specific virus across all eight competitions in tissue and MC/PM1 co-cultures are presented.
Each competition was done in done in duplicate. (A) Competitions including all four
subtypes; (B) competitions excluding subtype D. Mean values with SEM are shown.
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Chapter 4: Discussion and Conclusion
When comparing the pathogenicity of the dominant HIV-1 group M subtypes, patients
infected with HIV-1 subtype C progress to AIDS at a slower rate and consequently have
lower mortality rates compared to those infected with the other subtypes90. Disease
progression is driven by the repeated infection and killing of CD4+ T cells, leading to
gradual exhaustion and loss of this cell type. Evidence supports the notion that a virus’
ability to replicate in vitro in PBMCs or CD4+ T cells is a predictor of their effect on
disease progression in the host78–80,84. Consistent with this, previous studies by our group
performed pairwise competitions of HIV-1 subtypes in PBMCs or CD4+ T cells and
revealed subtype C to have the lowest replicative ability55,82. In fact, these competitions
revealed a general pathogenic fitness order of D = B > A > C55,90. Thus, it is possible that
HIV-1 subtype C is dominating the epidemic due to increased opportunities for infection.
With 2-5 more years of asymptomatic disease90, the infected host can transmit the virus
more frequently. However, the ability for a virus to replicate in blood cells and cause rapid
disease progression may or may not be related to its ability to efficiently infect genital
mucosa and thus transmit efficiently. Both opportunity for infection and transmission
efficiency are key factors of pathogen survival.

In this study, I investigated the ability of four dominant group M subtypes, subtypes A, B,
C, and D, to infect genital mucosal tissue as a measure of transmission efficiency.
Transmission fitness was assessed through both a) direct infection of tissue resident
susceptible cell populations and local replication; and b) uptake of the virus by tissue
resident cells that migrate out of the tissue to infect cells elsewhere in the body (i.e. draining
lymph nodes) for systemic infection. Using this model, I found that subtype D viruses
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outcompeted the other subtypes in both foreskin and cervical tissue. However, while
subtype D was also efficiently taken up and disseminated by cells migrating out of the
cervix, subtype B viruses were more efficient at this process in foreskin tissue. This was in
contrast to simple replicative fitness in CD4+ PM1 cells, where subtype D was far more
efficient at replicating than the other subtypes. Through this study, I confirmed the results
of previous reports indicating subtype C has lower replicative fitness than subtype D.
However, I did not observe that HIV-1 subtype C had even comparable, let alone greater
transmission efficiency than the other subtypes. My data suggests that the gradually
increasing prevalence and transmission of subtype C observed globally is not due to
inherent increased transmission fitness of subtype C viruses. Instead, subtype C’s
dominance of the epidemic may be due to its decreased pathogenicity, allowing infected
individuals more years between HIV seroconversion and the onset of AIDS symptoms
during which they may transmit the virus. In the long history of SIV infection in African
nonhuman primates, SIV and its natural hosts have evolved together resulting in the host
showing no signs of SIV-induced disease or simian AIDS108,109. Although highly
speculative, HIV-1 subtype C and the human host could be exhibiting a similar
phenomenon where its adaptation to the host has led it to have decreased pathogenicity.
For HIV-1 subtype B and D, their increased pathogenicity leads to faster disease
progression and mortality. Higher transmission fitness may compensate for this increased
replicative fitness. With less opportunity for infection, perhaps these subtypes evolved to
increase their transmission efficiency in order to survive and persist.

As described above, when viruses are competed directly on a susceptible CD4+ T cell line
(PM1 cells), it is predictive of in vivo pathogenic fitness and disease progression. Our
69

results in PM1 cells are comparable to the general fitness order determined in PBMCs55,82,
where subtype D and subtype B replicate more effectively than subtypes A and C. However,
in my study, subtype D outcompeted subtype B, accounting for over 80% of viral
replication in directly infected PM1 cells, in contrast to previous reports where subtype B
and D viruses were more evenly matched. Moreover, in competitions that did not include
subtype D I did not observe any difference in replicative fitness between subtypes A, B
and C.

The main limitation of my study is the utilization of only one subtype D virus, and only 23 viruses used for the other subtypes. By increasing the diversity of viruses within a subtype,
future studies will be able to more precisely attribute the results to actual subtype
differences. This may also be the reason for why there were no replicative fitness
differences between subtypes A, B, and C in the direct PM1 competitions. It is possible
that 14U is a particularly strong virus and doesn’t accurately represent subtype D as a whole.
Additionally, when analyzing the average replication of each individual virus, in foreskin
tissue the trends seen for subtypes A and C depended only on viruses 13U and 6Z,
respectively. During propagation of different subtype D viruses, only 14U was able to
infect U87.CD4.CCR5 cells and be produced at a titre high enough to be used in
transmission experiments. As such, future studies may need to re-insert the env gene from
the different subtype D primary viruses into the pREC_nflNL4-3env backbone, and should
include more representative viruses of each subtype in these competitions.

Nonetheless, my results are consistent with viral replication in PM1 cells being similar to
viral replication measured in both cervical and foreskin tissue. Although the relative
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transmission fitness differences between the other subtypes could not be discerned, subtype
D was the most effective at replicating in the tissue and in direct competitions on PM1 cells.
These studies need to be repeated with more representative viruses from each subtype, but
the pathogenic fitness of a virus may be able to predict its replication ability in genital
tissue.

In foreskin tissue, transmission of HIV-1 by migratory cells to PM1 cells does not follow
the trends seen in direct competitions on PM1 cells. Although subtype D was the most
effective at replicating in the tissue, subtype B was more efficiently taken up and
disseminated by cells migrating out of the foreskin. As demonstrated in vitro, cell-to-cell
transfer of HIV-1 is 100-1000 fold more efficient than infection carried out by cell-free
viral particles34–38. It has been argued that cell-to-cell transmission of HIV-1 is the main
route of transmission in vivo39,40, but the role that cell-to-cell vs. cell-free transmission
plays is still up for debate. However, the fact that the subtype most effective at replicating
in foreskin tissue is not the same subtype that is the most efficient at being transported to
PM1 cells is important. Thus, we need to consider these migrating cells in the context of
sexual transmission of HIV-1. Utilizing genital tissue in these investigations creates a more
complete picture of transmission events. Exclusively looking at replication in PM1 cells
may only represent a virus’ ability to infect and replicate in tissue resident cell populations.

Previous competition experiments in tissue explants demonstrate that there is a clear
“winner” as measured by one virus establishing the majority of viral replication in either
tissue or MC/PM155,82. As mentioned, it seems that in this model once a given virus has
the opportunity for infection in the tissue and/or migration out of the tissue to susceptible
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cells, the virus takes over and the majority of viral replication is attributed to that one virus.
This was the reason for the round-robin design of the competitions. In our study, when
tissue was infected with 150 IU of each virus this phenomenon was not clearly observed.
By examining the individual multi-virus competitions, viral replication was not measured
in 5/8 competitions, and the absence of viral replication was observed in at least one donor
for all four of the competitions lacking a subtype D virus. Additionally, when a virus did
establish infection the “winning” virus was not reproducible between competitions. With
an overall PCR efficiency of 45-50%, there was a high possibility that any trends in
transmission fitness observed were due to random infection events where true fitness
differences could not be confidently deduced. To rectify this issue, I increased the number
of infectious units to 750, 5x the original amount. With this increased MOI, I obtained
higher PCR amplification efficiencies (85-90%) and measurable viral replication in all but
two competitions in cervical tissue. This study helps refine the ex vivo explant assay and
its requirement for a greater number of infectious units to yield more consistent and
potentially more translatable results. The exact mechanism behind the increased number of
infectious units being a necessity still needs to be elucidated.

In conclusion, our trends suggest that HIV-1 subtype D dominates viral replication in the
tissue and is the most efficient at migrating out of the cervix for infection in PM1 cells.
However, in foreskin tissue the effect of migratory cells on subtype transmission may be
different than that of the cervix. Regardless, HIV-1 subtype C does not seem to have a
higher transmission fitness in the presence of the other subtypes. A virus’ pathogenic
fitness may be predictive of its ability to infect and replicate in tissue-resident susceptible
cell populations, however studies that include more representative viruses from each
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subtype will need to be done to confirm these results. The high prevalence of HIV-1
subtype C in the epidemic may be due to adaptation of the virus to the host and the faster
disease progression of subtypes B and D may require higher transmission efficiencies to
maintain itself in the HIV epidemic. Overall, to design effective vaccine strategies there is
a need to identify a phenotype of HIV-1 that is transmitted more favourably. At least in
foreskin tissue, the subtype that is transported to susceptible cells is different than the
subtype that replicates the most effectively in tissue. Therefore, we must continue to use
genital tissues in sexual transmission studies to more precisely understand transmission
events in the mucosa.
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